The New England Journal of Medicine published a study on the use of rivaroxaban in patients with recent acute coronary syndrome (ACS). The study, part of the ATLAS ACS 2–TIMI 51 trial, involved 15,526 patients randomized to receive either 2.5 mg or 5 mg of rivaroxaban twice daily or a placebo for a mean of 13 months. The primary endpoint was a composite of cardiovascular death, myocardial infarction, or stroke. Rivaroxaban significantly reduced the risk of this composite endpoint compared to placebo, with rates of 8.9% and 10.7% for the 2.5 mg and 5 mg doses, respectively. The 2.5 mg dose also showed a survival benefit, reducing cardiovascular death and death from any cause. However, rivaroxaban increased the risk of major bleeding and intracranial hemorrhage compared to placebo, without a significant increase in fatal bleeding. The 5 mg dose did not show a survival benefit. The study concluded that rivaroxaban reduced the risk of cardiovascular events in patients with recent ACS, but increased the risk of bleeding. The study was funded by Johnson & Johnson and Bayer Healthcare.The New England Journal of Medicine published a study on the use of rivaroxaban in patients with recent acute coronary syndrome (ACS). The study, part of the ATLAS ACS 2–TIMI 51 trial, involved 15,526 patients randomized to receive either 2.5 mg or 5 mg of rivaroxaban twice daily or a placebo for a mean of 13 months. The primary endpoint was a composite of cardiovascular death, myocardial infarction, or stroke. Rivaroxaban significantly reduced the risk of this composite endpoint compared to placebo, with rates of 8.9% and 10.7% for the 2.5 mg and 5 mg doses, respectively. The 2.5 mg dose also showed a survival benefit, reducing cardiovascular death and death from any cause. However, rivaroxaban increased the risk of major bleeding and intracranial hemorrhage compared to placebo, without a significant increase in fatal bleeding. The 5 mg dose did not show a survival benefit. The study concluded that rivaroxaban reduced the risk of cardiovascular events in patients with recent ACS, but increased the risk of bleeding. The study was funded by Johnson & Johnson and Bayer Healthcare.